Journal of Neurochemistry · 1987 · 39 citations · 14 references
MedicineMedicinal ChemistryPharmacologyMolecular PharmacologyNeurochemistryNeuropharmacologyEnzyme InhibitionLigand BindingLigand Binding KineticsMonoamine NeurochemistryDrug - Membrane InteractionsLigand SelectivityMonoamine Oxidase InhibitionMonoamine Oxidase InhibitorsMonoamine OxidasesMonoamine PharmacologyRadioligand Binding Assays
The reversible inhibitor of monoamine oxidase type B (MAO-B) [3H]Ro 16-6491 binds specifically and with high affinity to a single population of binding sites in human frontal cortex crude mitochondria and platelet membranes. In both tissues binding equilibrium was reached after 1 h incubation at 20 degrees C. Dissociation of bound radioactivity was relatively fast at 20 degrees C (t1/2 = 90-120 min) whereas at 0 degrees C [3H]Ro 16-6491 showed the characteristics of a slowly dissociating ligand. Inhibitors and substrates of MAO-B inhibited binding of [3H]Ro 16-6491, whereas MAO-A blockers were much less potent. Ro 16-6491 was also a substrate for MAO-B and a stable unidentified intermediate of the oxidation of Ro 16-6491 possessing high affinity for the enzyme may account for the marked MAO-B inhibitory effect of the drug. According to this hypothesis Ro 16-6491 would behave as a mechanism-based reversible inhibitor. In conclusion, [3H]Ro 16-6491 binds selectively to MAO-B and represents an excellent new radioligand probe for studying the regional tissue distribution of this enzyme in normal and pathological conditions.
14
Philip J. Geary · Biochemical Society Transactions · 1977 · 805 citations
Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
Sanford P. Markey, Jan N. Johannessen, Chuang C. Chiueh et al. · Nature · 1984 · 780 citations
Medicine, Neuroscience, Pharmacology +11